The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from CNW Group

Sophiris Bio Inc. Announces Election of Directors

Friday, June 14, 2013

Sophiris Bio Inc. Announces Election of Directors

16:00 EDT Friday, June 14, 2013

/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES/

SAN DIEGO, CA and VANCOUVER, June 14, 2013 /CNW/ - Sophiris Bio Inc. (TSX: SHS) (the "Company" or "Sophiris"), in accordance with Toronto Stock Exchange requirements, announced the voting results for the election of its Board of Directors at the Annual Meeting of Shareholders held on June 12, 2013 in Vancouver, British Columbia.  The director nominees, as listed in the Management Proxy Circular dated May 3, 2013, were elected as directors of the Company at the meeting.  The proxy votes submitted for each director were as follows:

       
  For       Withheld
Dr. Lars Ekman 85,131,509 99.99%   8,833 0.01%
Dr. John (Jack) Geltosky 85,131,509 99.99%   8,833 0.01%
Jim Heppell 85,031,509 99.87%   108,833 0.13%
Noah Knauf 85,131,509 99.99%   8,833 0.01%
William R. Rohn 85,131,509 99.99%   8,833 0.01%
Amit Sobti 85,133,509 99.99%   6,833 0.01%
Randall E. Woods 85,131,509 99.99%   8,833 0.01%
           

The results of the other matters considered at the meeting are reported in the Report of Voting Results as filed on SEDAR on June 14, 2013.

The Company's statutory filings are available at www.sedar.com.

About Sophiris Bio:
Sophiris Bio Inc. is a urology company developing a clinical-stage, targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), a market with significant demand. Sophiris' lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than surgical interventions, and without the sexual side effects seen with existing treatments. For more information, please visit www.sophirisbio.com.

 

SOURCE: Sophiris Bio, Inc.

For further information:

Lauren Glaser
Investor Relations
The Trout Group
646-378-2972
lglaser@troutgroup.com

James Beesley
Investor Relations 
Sequoia Partners
778-389-7715
james@sequoiapartners.ca

Michael Moore
Investor Relations
TMX Equicom Group 
619-467-7067
mmore@tmxequicom.com

Jason I. Spark
Media Relations
Canale Communications, Inc.
619-849-6005
jason@canalecomm.com

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections